P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation.Darowski, D., Jost, C., Stubenrauch, K., Wessels, U., Benz, J., Ehler, A., Freimoser-Grundschober, A., Brunker, P., Mossner, E., Umana, P., Kobold, S., Klein, C.
(2019) Protein Eng.Des.Sel. 32: 207-218
- PubMed: 31504896
- DOI: 10.1093/protein/gzz027
- PubMed Abstract:
Monoclonal antibody-based therapeutics are an integral part of treatment of different human diseases, and the selection of suitable antibody candidates during the discovery phase is essential. Here, we describe a novel, cellular screening approach fo ...
Monoclonal antibody-based therapeutics are an integral part of treatment of different human diseases, and the selection of suitable antibody candidates during the discovery phase is essential. Here, we describe a novel, cellular screening approach for the identification and characterization of therapeutic antibodies suitable for conversion into T cell bispecific antibodies using chimeric antigen receptor (CAR) transduced Jurkat-NFAT-luciferase reporter cells (CAR-J). For that purpose, we equipped a Jurkat-NFAT reporter cell line with a universal CAR, based on a monoclonal antibody recognizing the P329G mutation in the Fc-part of effector-silenced human IgG1-antibodies. In addition to scFv-based second generation CARs, Fab-based CARs employing the P329G-binder were generated. Using these anti-P329G-CAR-J cells together with the respective P329G-mutated IgG1-antibodies, we established a system, which facilitates the rapid testing of therapeutic antibody candidates in a flexible, high throughput setting during early stage discovery. We show that both, scFv- and Fab-based anti-P329G-CAR-J cells elicit a robust and dose-dependent luciferase signal if the respective antibody acts as an adaptor between tumor target and P329G-CAR-J cells. Importantly, we could demonstrate that functional characteristics of the antibody candidates, derived from the anti-P329G-CAR-J screening assay, are predictive for the functionality of these antibodies in the T cell bispecific antibody format.
Roche Innovation Center Zurich, Roche Pharma Research & Early Development, Wagistrasse 10 CH-8952 Schlieren, Switzerland.,Center for Integrated Protein Science Munich (CIPSM) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Lindwurmstraße 2a, 80337 Munich, Germany.,Roche Innovation Center Munich, Roche Pharma Research & Early Development, Nonnenwald 2 DE-82377 Penzberg, Germany.,Roche Innovation Center Basel, Roche Pharma Research & Early Development, Grenzacherstrasse 124 CH-4070 Basel, Switzerland.